Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY48.20 CNY
Change Today +0.20 / 0.42%
Volume 6.0M
As of 3:05 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

jiangsu hengrui medicine c-a (600276) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/15 - CNY52.37
52 Week Low
12/1/14 - CNY27.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JIANGSU HENGRUI MEDICINE C-A (600276)

Related News

No related news articles were found.

jiangsu hengrui medicine c-a (600276) Related Businessweek News

No Related Businessweek News Found

jiangsu hengrui medicine c-a (600276) Details

Jiangsu Hengrui Medicine Co., Ltd. researches, manufactures, and sells pharmaceutical products in China. It offers antineoplastic, angiomyocardiac, antibiotic, and other drugs, as well as APIs in the form of tablets, injectables, injections, oral solutions, capsules, and ointments. The company was founded in 1970 and is headquartered in Lianyungang, China.

Founded in 1970

jiangsu hengrui medicine c-a (600276) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jiangsu hengrui medicine c-a (600276) Key Developments

Hengrui Medicine to Build Biomedicine Production Base

Jiangsu Hengrui Medicine Co., Ltd. declared plans to invest in building biomedicine production base in the Economic and Technological Development Zone of Lianyungang with a total investment of CNY 1.5 billion.

Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody

Incyte Corporation announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the exclusive development and commercialization rights to SHR-1210 worldwide, with the exception of Mainland China, Hong Kong, Macau, and Taiwan. SHR-1210 is expected to enter proof-of-concept studies for the treatment of patients with advanced solid tumors in the coming months. Under the terms of the agreement, Incyte will acquire development and commercialization rights to SHR-1210 worldwide, with the exception of Mainland China, Hong Kong, Macau, and Taiwan, in exchange for an upfront payment of $25 million. The terms also include potential milestone payments of up to $770 million to Hengrui, consisting of $90 million for regulatory approval milestones, $530 million for commercial performance milestones, and $150 million based on clinical superiority. The terms also include tiered royalties to Hengrui on net sales of SHR-1210 in Incyte territories. Under the Agreement, Incyte and Hengrui will assume all financial obligations associated with the development and commercialization of SHR-1210 in their respective territories.

Jiangsu Hengrui Medicine Co., Ltd. Announces Earnings Results for the First Half of 2015

Jiangsu Hengrui Medicine Co., Ltd. announced earnings results for the first half of 2015. For the period, the company reported basic earnings per share of CNY 0.5424 and weighted average return on net assets of 12.52%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600276:CH CNY48.20 CNY +0.20

600276 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600276.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600276 Industry Range
Price/Earnings 50.5x
Price/Sales 11.1x
Price/Book 10.4x
Price/Cash Flow 50.7x
TEV/Sales 10.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JIANGSU HENGRUI MEDICINE C-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at